Lots of good info. Looks like they have final designs for 2 Phase 3 studies with MM-120 for GAD and one more Phase 3 for MDD. FDA must be onboard. HAM-A endpoint just 12 weeks into Phase 3. End of Phase 3 in one year, quite aggressive. Potential drug to market in mid 2026. And they are funded through 2026. Solid..This should pop soon.